Standout Papers

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group 2012 2026 2016 2021 1.1k
  1. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group (2012)
    Keith T. Flaherty, Caroline Robert et al. Zurich Open Repository and Archive (University of Zurich)

Immediate Impact

2 by Nobel laureates 32 from Science/Nature 67 standout
Sub-graph 1 of 20

Citing Papers

A vision–language foundation model for precision oncology
2025 StandoutNature
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
2024 Standout
5 intermediate papers

Works of Frank Wu being referenced

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
2015
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
2012 Standout

Author Peers

Author Last Decade Papers Cites
Frank Wu 1319 986 278 36 1.9k
Maria Colombino 933 835 202 57 1.6k
Jeff Sosman 1156 1164 301 37 2.1k
Mary Varterasian 1107 810 262 42 1.9k
David A. Proia 1832 929 370 56 2.5k
Scott A. Boerner 1172 835 332 39 2.2k
Luna Musib 1425 944 475 76 2.5k
Joel Morris 1343 1114 358 29 1.9k
Nobuya Ishii 1339 791 588 49 2.1k
R A McClelland 972 1248 242 45 2.4k
Maria Cristina Sini 1009 696 185 57 1.5k

All Works

Loading papers...

Rankless by CCL
2026